Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04430699 · ClinicalTrials.gov registry record · Phase 2
Cisplatin+Pembrolizumab+RT in Vulvar Cancer
A Phase 2 study of Vulvar Cancer and Vulvar Squamous Cell Carcinoma, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT04430699 is a Phase 2 study of Vulvar Cancer and Vulvar Squamous Cell Carcinoma that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 24 participants, below the 452-participant average among 17 other Vulvar Cancer trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT04430699, a Phase 2 study of Vulvar Cancer and Vulvar Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research is being done to see how well the combination of a standard of care drug, investigational drug, and radiation therapy work against unresectable vulvar squamous cell carcinoma. This research study involves the following: * Cisplatin (standard of care drug) * Pembrolizumab (investigational drug) * Radiation Therapy (standard of care intervention)
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Cisplatin
- RADIATION Radiation Therapy
Study Locations (2)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2020-07-29 |
| Est. Completion | 2028-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04430699
The ClinicalTrials.gov registry entry for NCT04430699 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 452-participant average among 17 other Vulvar Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Vulvar Cancer appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT04430699 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04430699 about?
NCT04430699 is a clinical study titled "Cisplatin+Pembrolizumab+RT in Vulvar Cancer". This research is being done to see how well the combination of a standard of care drug, investigational drug, and radiation therapy work against unresectable vulvar squamous cell carcinoma. This research study involves the following: * Cisplatin (standard of care drug) * Pembrolizumab (investigati...
What is the current status of trial NCT04430699?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2020-07-29. Estimated completion is 2028-01-30.
What conditions does trial NCT04430699 study?
This clinical trial studies the following conditions: Vulvar Cancer, Vulvar Squamous Cell Carcinoma.
What interventions are being tested in trial NCT04430699?
The interventions under investigation include: Pembrolizumab (DRUG), Cisplatin (DRUG), Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT04430699?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04430699 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vulvar Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
RECRUITING · Phase 2
-
Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies
RECRUITING · Phase 2
-
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
RECRUITING · Phase 2
-
Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers
ACTIVE NOT RECRUITING · Phase 2
-
ASk Questions in GYnecologic Oncology (ASQ-GYO)
RECRUITING · NA
-
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.